Skip to main content

Table 1 Descriptive statistics for sociodemographic and clinical variables (n = 54)

From: Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden

Age: Mean (SD) 58.7 (10.8)
  Median 61
Sex: n (%) Men 30 (55.6%)
  Women 24 (44.4%)
Time since diagnosis (weeks): Mean (SD) 52.5 (70.5)
  Median 19
Diagnosis: n (%) Lung cancer 14 (25.9%)
  Breast cancer 11 (20.4%)
  Lymphoma 8 (14.8%)
  Pancreatic or cholangiocellular cancer 8 (14.8%)
  Colorectal cancer 7 (13.0%)
  Ovarian cancer 4 (7.4%)
  Stomach cancer 1 (1.9%)
  Oesophagic cancer 1 (1.9%)
Chemotherapy: n (%)* Taxane monotherapy 89 (15.9%)
  Gemcitabine 59 (10.5%)
  Capecitabine plus platin 33 (5.9%)
  Irinotecan and capecitabine 33 (5.9%)
  Ribomustin 30 (5.3%)
  Platin plus etoposid 28 (5.0%)
  Taxane plus Bevacizumab 25 (4.5%)
  Taxane plus platin 25 (4.5%)
  Irinotecan, capecitabine and bevacizumab 22 (3.9%)
  Pemetrexed plus platin 19 (3.4%)
  Vinorelbin plus platin 19 (3.4%)
  Irinotecan 17 (3.0%)
  Other 28.9%
Chemotherapy line: n (%)* Neoadjuvant 58 (10.3%)
  Adjuvant 91 (16.2%)
  Curative 26 (4.6%)
  1. Line palliative 183 (32.6%)
  2. Line palliative 111 (19.8%)
  3. Line or more palliative 92 (16.4%)
  1. *percentages refer to total number of assessments (n = 561).